Titre du document / Document title

Clobetasol propionate lotion, an efficient and safe alternative to clobetasol propionate emollient cream in subjects with moderate to severe plaque-type psoriasis

Auteur(s) / Author(s)

LOWE Nicholas ⁽¹⁾ ; FELDMAN Steven R. ⁽²⁾ ; SHERER Daniel ⁽³⁾ ; WEISS Jonathan ⁽⁴⁾ ; SHAVIN Joel S. ⁽⁴⁾ ; YIN LUI LIN ⁽⁵⁾ ; FOLEY Valerie ⁽⁵⁾ ; SOTO Pascale ⁽⁶⁾ ;

Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)

⁽¹⁾ Clinical Research Specialists, Santa Monica CA, ETATS-UNIS
⁽²⁾ Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, ETATS-UNIS
⁽³⁾ Mount Sinai School of Medicine, New York, NY, ETATS-UNIS
⁽⁴⁾ Gwinnett Clinical Research Center, Snellville, GA, ETATS-UNIS
⁽⁵⁾ Galderma R&D, Princeton, NJ, ETATS-UNIS
⁽⁶⁾ Galderma Medical Affairs, Sophia Antipolis, FRANCE

Résumé / Abstract

Background: Various formulations of clobetasol propionate are currently used to treat psoriasis due to its anti-inflammatory, anti-pruritic, vasoconstrictive and immunomodulating properties. Objective: To assess the efficacy, safety and remission profile of clobetasol propionate lotion compared to that of clobetasol propionate emollient cream and lotion vehicle in subjects with moderate to severe plaque-type psoriasis. Methods: Multicentre, investigator-blind, randomized, active- and vehicle-controlled, parallel-group study. Results: A total of 192 subjects were treated: 82 with clobetasol propionate lotion, 81 with clobetasol propionate cream and 29 with the vehicle. Clobetasol propionate lotion was significantly more effective than vehicle lotion and was comparable in efficacy to the emollient cream after 4 weeks of treatment. Treatment success was higher for subjects in the clobetasol propionate lotion group than in the emollient cream group after 4 weeks of a treatment-free follow-up period. Clobetasol propionate lotion was safe and well tolerated. Conclusion: The present study demonstrates that clobetasol propionate lotion is an efficacious, safe and well-tolerated alternative to the currently available emollient cream formulation, while showing a better remission profile after 4 weeks of treatment-free follow-up period.

Revue / Journal Title

Journal of dermatological treatment   ISSN 0954-6634 

Source / Source

2005, vol. 16, n^o3, pp. 158-164 [7 page(s) (article)] (12 ref.)

Langue / Language

Anglais

Editeur / Publisher

Taylor & Francis, Oslo, NORVEGE  (1989) (Revue)

Mots-clés anglais / English Keywords

Vascular disease ; Cardiovascular disease ; Skin disease ; Dosage form ; Corticosteroid ; Skin atrophy ; Antiinflammatory agent ; Treatment ; Antipsoriatic agent ; Telangiectasia ; Remission ; Quality of life ; Psoriasis ; Human ; Cream ; Emollient ; Lotion ; Clobetasol propionate ;

Mots-clés français / French Keywords

Vaisseau sanguin pathologie ; Appareil circulatoire pathologie ; Peau pathologie ; Forme pharmaceutique ; Corticostéroïde ; Atrophie peau ; Antiinflammatoire ; Traitement ; Antipsoriasique ; Télangiectasie ; Rémission ; Qualité vie ; Psoriasis ; Homme ; Crème ; Emollient ; Lotion ; Clobétasol propionate ;

Mots-clés espagnols / Spanish Keywords

Vaso sanguíneo patología ; Aparato circulatorio patología ; Piel patología ; Forma farmacéutica ; Corticoesteroide ; Atrofia piel ; Antiinflamatorio ; Tratamiento ; Antipsoriásico ; Telangiectasia ; Remisión ; Calidad vida ; Psoriasis ; Hombre ; Crema ; Emoliente ; Loción ; Clobetasol propionato ;

Mots-clés d'auteur / Author Keywords

Clobetasol propionate ; plaque-type psoriasis ; quality of life ; remission ; skin atrophy ; telangiectasia ;

Localisation / Location

INIST-CNRS, Cote INIST : 22488, 35400013187035.0050